Astellas Pharma Global Development, Inc.

This early-phase study tested a lab-modified virus (ASP1012) designed to infect and kill cancer cells while alerting the immune system. It involved 15 adults with advanced solid tumors who had exhausted standard treatments. Some participants also received the immunotherapy pembro…

This study tested a drug called gilteritinib, which targets a specific genetic change (FLT3/ITD) in acute myeloid leukemia (AML), combined with standard chemotherapy. It included 9 children, teens, and young adults whose leukemia had come back or not responded to treatment. The g…

This study tested an experimental drug called enfortumab vedotin, alone or with other cancer treatments, in people with advanced or muscle-invasive bladder cancer. The goal was to see how safe the combinations were and whether they could shrink tumors. The study included 348 part…

This study tested a drug called enfortumab vedotin in 37 people with a type of bladder cancer that hasn't spread into the muscle wall. The drug was placed directly into the bladder using a thin tube. The main goals were to check for side effects and see if the drug could help tre…

This early-stage study tested a new treatment called ASP2802 for people with B-cell lymphoma that came back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better fight cancer, and then given back along with…

This early-stage study tested a new drug called ASP5502 in healthy adults and people with Sjögren's syndrome, a condition where the immune system attacks moisture-producing glands. The main goal was to check safety and how well the drug is tolerated. Participants took single or m…

This early-stage study tested a new drug, ASP2074, in 23 adults with advanced solid tumors that had spread or couldn't be removed. The main goals were to check for side effects and find a safe dose. Participants received the drug as an infusion and were monitored closely. The stu…